Clearmind Medici Stock Price, News & Analysis

Clearmind Medicine Inc. (NASDAQ: CMND) has successfully closed a public offering, raising approximately US$3.5 million in gross proceeds. The offering included 4,505,718 common shares along with pre-funded warrants and common warrants, each priced at US$0.78, with warrants exercisable over five years. The funds will be utilized for general corporate purposes, including operating expenses, R&D, and potential acquisitions. This offering, made exclusively in the U.S., was facilitated by Aegis Capital Corp., acting as the placement agent. Clearmind focuses on developing psychedelic-derived therapeutics for under-treated health issues, particularly alcohol use disorder, and holds 13 patent families with intentions for further acquisitions of intellectual property.

Clearmind Medicine Inc. (NASDAQ: CMND) announced a public offering in the U.S., aiming to raise approximately US$3.5 million. This offering involves the sale of 4,505,718 common shares and common warrants, each warrant exercisable at US$0.78. The offering is expected to close on April 6, 2023, pending customary conditions. Proceeds will support general corporate purposes, including operational expenses and research and development for their psychedelic-derived therapeutics. Aegis Capital Corp. serves as the exclusive placement agent for this transaction. This offering does not include Canadian residents.

Clearmind Medicine Inc. (NASDAQ: CMND) has submitted an Investigational New Drug (IND) application to the FDA for its first-in-human Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder (AUD). The trial aims to start in Q2 2023 if approved. CMND-100's active ingredient, MEAI, is a novel psychoactive molecule that shows promise in reducing alcohol consumption through interactions with serotonergic and adrenergic receptors. The treatment addresses a significant healthcare issue, with 28 million adults in the U.S. facing AUD, leading to substantial economic losses.

Clearmind Medicine Inc. (Nasdaq: CMND) has appointed Professor Henry R. Kranzler, M.D., to its Scientific Advisory Board. Professor Kranzler, a leading expert in addiction medicine, serves at the University of Pennsylvania and has extensive experience in the genetics and pharmacological treatment of substance dependence. His appointment is seen as a strategic move to enhance Clearmind's development of psychedelic-derived therapeutics for alcohol use disorder and other substance use treatments. Clearmind is focused on addressing major health issues through innovative drug candidates, bolstered by its portfolio of 13 patent families.

Clearmind Medicine Inc. (NASDAQ: CMND) announced the submission of three provisional patent applications to the USPTO for unique psychedelic-based compounds in collaboration with SciSparc Ltd. The applications focus on combinations of MDMA, Ibogaine, and Ketamine with Palmitoylethanolamide (PEA), aiming to expand their intellectual property (IP) portfolio within the psychedelic space. Clearmind currently holds 29 patents in 13 families, with plans for further innovation in mental health treatments. CEO Dr. Adi Zuloff-Shani emphasized the goal of addressing unmet patient needs through innovative medicine.

Clearmind Medicine Inc. (NASDAQ: CMND) has filed three provisional patent applications with the USPTO in collaboration with SciSparc Ltd. to develop innovative psychedelic-based treatments. The patents encompass combinations of LSD, psilocybin, DMT, and the active ingredient of CannAmide™, aimed at enhancing efficacy and safety for mental health therapies. Clearmind boasts 23 patents across seven families, positioning itself strongly in the psychedelic sector. The company's strategy focuses on providing safer, more effective treatments for mental health disorders and expanding their intellectual property portfolio.

Clearmind Medicine Inc. (NASDAQ: CMND) will attend the 2023 OurCrowd Global Investor Summit on February 15 in Jerusalem. CEO Dr. Adi Zuloff-Shani will discuss the company’s recent Nasdaq IPO with David Huberman from Greenberg Traurig. This session, titled “IPOs in a Down Market,” aims to provide insights into the IPO process and the challenges faced in the current economic climate. Clearmind focuses on developing psychedelic-derived therapeutics to address significant health issues, holding seven patent families, and aims to expand its intellectual property portfolio.

Clearmind Medicine Inc. (NASDAQ: CMND) will host a virtual investor conference titled “Psychedelics for Obesity” on February 28, 2023, at 8:30 AM EST. The event will highlight recent positive pre-clinical results for its drug candidate MEAI, aimed at treating obesity and metabolic syndrome. Professor Joseph Tam, leading the study from Hebrew University's Institute for Drug Research, will discuss these findings. CEO Dr. Adi Zuloff-Shani will outline the company's achievements and future goals. Clearmind focuses on developing psychedelic-derived therapeutics for significant health issues and is listed on NASDAQ under CMND.

Clearmind Medicine Inc. (NASDAQ: CMND) has announced promising results from a pre-clinical trial involving 2-Fluorodeschloroketamine (2-FDCK), an analogue of Ketamine, aimed at treating Major Depressive Disorder (MDD). Conducted in collaboration with Bar-Ilan University, the trial evaluated the effects of 2-FDCK on rodent models of depression. Results indicated superior efficacy of 2-FDCK over Ketamine, especially in chronic treatment settings. Clearmind's CEO highlighted the significance of these findings for patients with treatment-resistant depression, emphasizing the company's commitment to developing innovative psychedelic-derived therapeutics.